Hypogonadism Clinical Trial
Official title:
Efficacy and Safety of a Mixed Extract of Fenugreek Seed and Lespedeza Cuneata in the Treatment of Testosterone Deficiency Syndrome: A Randomized, Double-blind, Placebo-Controlled Clinical Trial
Objective: The aim of this study was to investigate the efficacy and safety of a mixed
extract of fenugreek seed and Lespedeza cuneata (TFG) for the treatment of testosterone
deficiency syndrome (TDS).
Design: Patients were instructed to take a placebo capsule or 200 mg TFG capsule twice per
day for 8 weeks.
Outcome measures: The primary efficacy variable was the change from baseline in the Aging
Males' Symptoms scale (AMS), as well as levels of serum total testosterone and free
testosterone. Secondary efficacy measurements included changes from baseline in the number
of 'yes' answers on the Androgen Deficiency in the Aging Male questionnaire (ADAM), levels
of serum total cholesterol, HDL-C, LDL-C, triglyceride, perceived stress scale (PSS-10), all
domain scores of the International Index of Erectile Function (IIEF), as well as changes in
body composition.
Testosterone deficiency syndrome (TDS) is "a clinical and biochemical syndrome associated
with advancing age and characterized by symptoms of a deficiency in serum testosterone
levels". TDS can cause a significant decrease in quality of life and has many adverse
effects on multiple organs in terms of men's health. In addition to the detrimental effect
of sexual functions, men with TDS tend to have increased waist circumference, hyperglycemia,
hypertriglyceridemia, hyperlipidemia, and a history of diabetes. TDS can be treated with
testosterone replacement therapy (TRT). TRT should be initiated on an individualized basis
in TDS patients who have clinical signs and symptoms of androgen deficiency if the benefits
of treatment appear to outweigh the potential risks and only after thorough discussion with
the patient. Different preparations of testosterone are currently available. The majority of
clinical data shows that TRT is very safe and effective. There is currently no evidence that
testosterone treatment increases the risk of prostate disease using modern guidelines.
However, the fear of prostate cancer and the risk of erythrocytosis may represent the main
limitations of TRT in aging men. Additionally, TRT cannot improve the function of Leydig
cells (which produce testosterone), but only compensate for the lack of testosterone.
Limited research has focused on the use of herbal medicine to improve male health,
particularly to increase testosterone levels and support healthy sexual function. Despite
the increasing availability of effective conventional medical treatments, plant-derived and
herbo-mineral remedies continue to be a popular alternative for men seeking to improve
sexual function.
Trigonella foenum-graecum Linn, also known as fenugreek, is an aromatic annual plant that
reaches heights of 30-60 cm. It is found wild in Kashmir, Punjab, and the upper Gangetic
plains, and is widely cultivated in many parts of India. It is used internally as an
abortifacient, antispasmodic, appetite stimulant, blood cleanser, laxative, tonic, and
expectorant. It is also indicated externally for abscesses, boils, galactagogue, and for its
demulcent and emollient properties. The seeds contain diosgenin along with three minor
steroidal saponins (similagenin, savsalpogenin, and yuccagenin), choline, trimethylamine (a
sex hormone in frogs), vitamins (A, B2, B6, B12, D), lysine, l-tryptophan rich proteins,
mucilaginous fiber, coumarin, fenugreekine, nicotinic acid, sapogenins, phytic acid,
scopletin and trigonelline, calcium, iron, β-carotene, and other vitamins and essential
oils.
Previous studies have suggested that Trigonella foenum-graecum seed extract has positive
effects on sexual health and quality of life, and that it demonstrates anabolic and
androgenic activity in young patients. It is believed that these positive effects are due to
increased testosterone, including free testosterone, and that Trigonella foenum-graecum seed
extract may be an effective treatment for the symptoms of possible testosterone deficiency
in aging men. The basis for this androgenic activity may be due to the fact that Trigonella
foenum-graecum seeds contain soluble steroidal saponins, specifically furostanol glycosides,
which are responsible for complexing cholesterol in the cell membrane. Other studies have
found that Trigonella foenum-graecum increases testosterone and free testosterone,
suggesting that it may be an incomplete 5-alpha reductase and aromatase inhibitor. The
investigators investigated the efficacy and safety of a mixed extract of Trigonella
foenum-graecum seed and lespedeza cuneata (TFG) for the treatment of TDS.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03126656 -
Effects of Testosterone on Myocardial Repolarization
|
Phase 4 | |
Terminated |
NCT02419105 -
Effects of Transdermal Testosterone and/or Monthly Vitamin D on Fall Risk in Pre--frail Hypogonadal Seniors
|
Phase 3 | |
Withdrawn |
NCT02137265 -
Assessing the Efficacy of Clomiphene Citrate in Patients With Azoospermia and Hypoandrogenism
|
N/A | |
Completed |
NCT02222558 -
Oral Testosterone for the Treatment of Hypogonadism in Males
|
Phase 2 | |
Completed |
NCT02233751 -
Pharmacokinetic Study of Subcutaneous Testosterone Enanthate
|
Phase 1 | |
Completed |
NCT01887418 -
Pharmacokinetic Study of Testosterone Enanthate
|
Phase 1/Phase 2 | |
Terminated |
NCT01092858 -
NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH)
|
Phase 4 | |
Completed |
NCT00624624 -
Follow-up of Serum Androgen Profile After Bariatric Surgery in Men With Obesity Related Hypogonadotropic Hypogonadism
|
N/A | |
Completed |
NCT00752869 -
Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement
|
Phase 4 | |
Completed |
NCT00613288 -
Testosterone and Lipolysis, Insulin Sensitivity and Protein Metabolism
|
N/A | |
Completed |
NCT00119483 -
Older Men and Testosterone
|
N/A | |
Completed |
NCT00838838 -
Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis
|
N/A | |
Completed |
NCT00004438 -
Leuprolide in Treating Adults With Hypogonadotropism
|
N/A | |
Withdrawn |
NCT00398034 -
Analgesic Efficacy of Testosterone Replacement in Hypogonadal Opioid-treated Chronic Pain Patients: A Pilot Study.
|
Phase 2 | |
Completed |
NCT02921386 -
The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate
|
Phase 2 | |
Completed |
NCT02937740 -
Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™
|
Phase 4 | |
Completed |
NCT01717768 -
Oral Testosterone for the Treatment of Hypogonadism
|
Phase 2 | |
Terminated |
NCT01460654 -
Testosterone and Alendronate in Hypogonadal Men
|
Phase 2 | |
Completed |
NCT00998933 -
Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure
|
Phase 1 | |
Completed |
NCT00857454 -
A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations
|
Phase 3 |